Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
Katz DA, Morris JD, Chu MP, David KA, Thieblemont C, Morley NJ, Khan SS, Viardot A, Martín García-Sancho A, Rodríguez-García G, Bastos-Oreiro M, Lee ST, Kormany W, Chen Y, Wong HL, Anderson AA, Katlinskaya Y, Avilion AA, Dai T, González-Barca E. Katz DA, et al. Among authors: viardot a. Leuk Lymphoma. 2022 Sep;63(9):2063-2073. doi: 10.1080/10428194.2022.2064981. Epub 2022 May 3. Leuk Lymphoma. 2022. PMID: 35503708 Free article. Clinical Trial.
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia.
Gökbuget N, Ihrig K, Stadler M, Stelljes M, Elmaagacli A, Starck M, Raffel S, Stoltefuss A, Viardot A, Kreuzer KA, Heidenreich D, Renzelmann A, Wäsch R, Topp MS, Ritter B, Reimer P, Beck J, Westermann J, Wendelin K, Alakel N, Hanoun M, Serve H, Hoelzer D. Gökbuget N, et al. Among authors: viardot a. Haematologica. 2023 Jul 1;108(7):1758-1767. doi: 10.3324/haematol.2022.281820. Haematologica. 2023. PMID: 36779593 Free PMC article.
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC. Topp MS, et al. Among authors: viardot a. J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576633 Clinical Trial.
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
Wagner-Johnston ND, Schuster SJ, deVos S, Salles G, Jurczak WJ, Flowers CR, Viardot A, Flinn IW, Martin P, Xing G, Rajakumaraswamy N, Gopal AK. Wagner-Johnston ND, et al. Among authors: viardot a. Leuk Lymphoma. 2021 May;62(5):1077-1087. doi: 10.1080/10428194.2020.1855344. Epub 2020 Dec 10. Leuk Lymphoma. 2021. PMID: 33300385 Clinical Trial.
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
Kaddu-Mulindwa D, Lesan V, Berdel C, Stilgenbauer S, Bewarder M, Thurner L, Witzens-Harig M, Viardot A, Soekler M, Keller U, Truemper L, Christofyllakis K, Fleser O, Bittenbring JT, Poeschel V, Held G, Jagoda P. Kaddu-Mulindwa D, et al. Among authors: viardot a. Leuk Lymphoma. 2022 Feb;63(2):326-334. doi: 10.1080/10428194.2021.1975193. Epub 2021 Oct 20. Leuk Lymphoma. 2022. PMID: 34668817
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Fowler NH, et al. Among authors: viardot a. Nat Med. 2022 Feb;28(2):325-332. doi: 10.1038/s41591-021-01622-0. Epub 2021 Dec 17. Nat Med. 2022. PMID: 34921238 Free article. Clinical Trial.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, María Ferreri AJ, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Paule I, Zia A, Awasthi R, Han X, Germano D, O'Donovan D, Ramos R, Maier HJ, Masood A, Thieblemont C, Schuster SJ. Dreyling M, et al. Among authors: viardot a. Blood. 2024 Apr 25;143(17):1713-1725. doi: 10.1182/blood.2023021567. Blood. 2024. PMID: 38194692 Free article. Clinical Trial.
129 results